Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study

Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in CKD: A Meta-analysis of Patient-Level Data From 3 Randomized Trials

(2014) Patrick H. Pun et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Sudden Cardiac Arrest in Hemodialysis Patients with Wearable Cardioverter Defibrillator

(2013) Chingping Wan et al.   ANNALS OF NONINVASIVE ELECTROCARDIOLOGY

Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies

(2013) Nader Makki et al.   EUROPACE

ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy

(2013) Andrea M. Russo et al.   HEART RHYTHM

Sudden Cardiac Death in Hemodialysis Patients: A Comprehensive Care Approach to Reduce Risk

(2012) Patrick H. Pun et al.   BLOOD PURIFICATION

The National Cardiovascular Data Registry (NCDR) Data Quality Brief

(2012) John C. Messenger et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Trends in the Use and Outcomes of Implantable Cardioverter-Defibrillators in Patients Undergoing Dialysis in the United States

(2011) David M. Charytan et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Outcomes of patients with chronic kidney disease and implantable cardiac defibrillator: Primary versus secondary prevention

(2011) Fadi G. Hage et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Risk of arrhythmic and nonarrhythmic death in patients with heart failure and chronic kidney disease

(2010) Alawi A. Alsheikh-Ali et al.   AMERICAN HEART JOURNAL

Meta-Analysis of Mortality in Dialysis Patients With an Implantable Cardioverter Defibrillator††Disclosures: Dr. Bhatt has received research grants (directly to the institution) from Bristol-Myers Squibb, New York, New York; Eisai Inc., Woodcliff Lake, New Jersey; Ethicon, Inc., Somerville, New Jersey; Heartscape Technologies, Inc., Columbia, Maryland; Sanofi-Aventis, Paris, France; and The Medicines Company, Parsippany, New Jersey. Dr. Bhatt is a consultant for or member of the advisory boards (honoraria waived or donated to nonprofit organizations) of Arena Pharmaceuticals, Inc., San Diego, California; AstraZeneca PLC, London, United Kingdom; Bristol-Myers Squibb; Cardax Pharmaceuticals, Inc., Aiea, Hawaii; Centocor, Inc., Horsham, Pennsylvania; Cogentus Pharmaceuticals, Palo Alto, California; Daiichi Sankyo, Inc., Parsippany, New Jersey; Eisai Inc.; Eli Lilly and Company, Indianapolis, Indiana; GlaxoSmithKline PLC, London, United Kingdom; Johnson & Johnson, New Brunswick, New Jersey; Ortho-McNeil, Raritan, New Jersey; Medtronic, Inc., Minneapolis, Minnesota; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; Otsuka Pharmaceutical Company, Ltd., Tokyo, Japan; ParinGenix, Inc., Weston, Florida; PDL BioPharma, Inc., Redwood City, California; Philips Medical Systems, Andover, Massachusetts; Portola Pharmaceuticals Inc., South San Francisco, California; Sanofi-Aventis; Schering-Plough Corporation, Kenilworth, New Jersey; The Medicines Company; and Vertex Pharmaceuticals, Inc., Cambridge, Massachusetts.

(2009) Rahul Sakhuja et al.   AMERICAN JOURNAL OF CARDIOLOGY

Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation

(2009) Atul Aggarwal et al.   HEART RHYTHM

Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease

(2009) Patrick H. Pun et al.   KIDNEY INTERNATIONAL

Prevention of sudden cardiac death: rationale and design of the Implantable Cardioverter Defibrillators in Dialysis patients (ICD2) Trial – a prospective pilot study

(2008) Mihaly K. de Bie et al.   CURRENT MEDICAL RESEARCH AND OPINION